$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq

$vbivq Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222021559 Filed on August 08, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$317.0K	$346.0K	$126.0K
YoY Change	196.26%	143.66%	-58.0%
Cost Of Revenue	$2.672M	$2.522M	$2.754M
YoY Change	8.35%	-4.25%	14.27%
Gross Profit	-$2.355M	-$2.176M	-$2.628M
YoY Change	-0.17%	-12.68%	24.55%
Gross Profit Margin	-742.9%	-628.9%	-2085.71%
Selling, General & Admin	$14.22M	$15.08M	$10.93M
YoY Change	46.7%	61.03%	61.93%
% of Gross Profit
Research & Development	$4.983M	$5.643M	$2.362M
YoY Change	67.66%	23.16%	-65.47%
% of Gross Profit
Depreciation & Amortization	$526.0K	$542.0K	$473.0K
YoY Change	18.2%	15.07%	5.11%
% of Gross Profit
Operating Expenses	$21.88M	$23.25M	$13.29M
YoY Change	72.72%	40.2%	-2.19%
Operating Profit	-$21.56M	-$22.90M	-$15.92M
YoY Change	43.49%	39.3%	1.4%
Interest Expense	$958.0K	$901.0K	-$5.334M
YoY Change	-216.4%	6.63%	173.54%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$25.21M	-$45.70M	-$21.25M
YoY Change	59.08%	161.5%	20.42%
Income Tax
% Of Pretax Income
Net Earnings	-$25.21M	-$45.70M	-$21.25M
YoY Change	59.08%	161.5%	20.44%
Net Earnings / Revenue	-7952.37%	-13207.8%	-16868.25%
Basic Earnings Per Share	-$0.10	-$0.18	-$2.47
Diluted Earnings Per Share	-$97.61K	-$177.0K	-$82.30K
COMMON SHARES
Basic Shares Outstanding	258.3M shares	258.3M shares	8.609M shares
Diluted Shares Outstanding	8.609M shares	8.609M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$83.55M	$82.41M	$101.3M
YoY Change	-39.22%	-38.96%	-24.15%
Cash & Equivalents	$83.55M	$82.41M	$101.3M
Short-Term Investments
Other Short-Term Assets	$4.008M	$4.468M	$4.082M
YoY Change	-32.13%	6.05%	13.39%
Inventory	$5.796M	$4.050M	$4.057M
Prepaid Expenses	$2.730M	$1.685M
Receivables	$132.0K	$135.0K	$102.0K
Other Receivables	$2.350M	$2.313M	$2.769M
Total Short-Term Assets	$96.22M	$92.75M	$112.3M
YoY Change	-34.9%	-36.51%	-22.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.15M	$11.02M	$14.69M
YoY Change	2.12%	-3.39%	27.76%
Goodwill	$2.104M	$2.237M
YoY Change
Intangibles	$57.73M	$61.38M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.349M	$1.396M	$1.446M
YoY Change	23.31%	46.79%	80.75%
Total Long-Term Assets	$75.79M	$79.41M	$81.66M
YoY Change	-0.83%	1.1%	5.64%
TOTAL ASSETS
Total Short-Term Assets	$96.22M	$92.75M	$112.3M
Total Long-Term Assets	$75.79M	$79.41M	$81.66M
Total Assets	$172.0M	$172.2M	$194.0M
YoY Change	-23.29%	-23.36%	-12.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.67M	$5.617M	$3.927M
YoY Change	211.51%	225.62%	131.0%
Accrued Expenses	$13.50M	$15.07M	$14.67M
YoY Change	-2.81%	-1.95%	29.85%
Deferred Revenue	$597.0K	$864.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$8.780M	$4.744M
YoY Change
Total Short-Term Liabilities	$34.68M	$40.53M	$33.99M
YoY Change	5.26%	55.49%	42.82%
LONG-TERM LIABILITIES
Long-Term Debt	$48.42M	$21.16M	$24.79M
YoY Change	73.3%	-22.91%	55.9%
Other Long-Term Liabilities	$5.094M	$4.908M	$5.663M
YoY Change	59.39%	62.09%	82.68%
Total Long-Term Liabilities	$53.51M	$26.07M	$30.45M
YoY Change	71.87%	-14.47%	60.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.68M	$40.53M	$33.99M
Total Long-Term Liabilities	$53.51M	$26.07M	$30.45M
Total Liabilities	$88.19M	$66.60M	$64.44M
YoY Change	37.62%	17.78%	50.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$468.5M	-$443.3M
YoY Change
Common Stock	$442.3M	$442.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$83.82M	$105.6M	$129.6M
YoY Change
Total Liabilities & Shareholders Equity	$172.0M	$172.2M	$194.0M
YoY Change	-23.29%	-23.36%	-12.96%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$25.21M	-$45.70M	-$21.25M
YoY Change	59.08%	161.5%	20.44%
Depreciation, Depletion And Amortization	$526.0K	$542.0K	$473.0K
YoY Change	18.2%	15.07%	5.11%
Cash From Operating Activities	-$17.27M	-$17.45M	-$19.93M
YoY Change	328.64%	62.75%	200.08%
INVESTING ACTIVITIES
Capital Expenditures	-$1.300M	-$1.077M	-$515.0K
YoY Change	205.88%	169.25%	-8.04%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$1.300M	-$1.077M	-$515.0K
YoY Change	205.88%	-104.35%	-8.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	19.44M	0.000	12.00K
YoY Change	175.51%	-100.0%	-99.94%
NET CHANGE
Cash From Operating Activities	-17.27M	-17.45M	-19.93M
Cash From Investing Activities	-1.300M	-1.077M	-515.0K
Cash From Financing Activities	19.44M	0.000	12.00K
Net Change In Cash	863.0K	-18.53M	-20.43M
YoY Change	-66.81%	-169.25%	-241.66%
FREE CASH FLOW
Cash From Operating Activities	-$17.27M	-$17.45M	-$19.93M
Capital Expenditures	-$1.300M	-$1.077M	-$515.0K
Free Cash Flow	-$15.97M	-$16.37M	-$19.41M
YoY Change	343.11%	58.62%	219.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Address Address Line1 EntityAddressAddressLine1	160 Second Street
	dei	Entity Central Index Key EntityCentralIndexKey	0000764195
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2021	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q2	VBIV	Common Shares Issued Upon Cashless Exercise Of Warrants CommonSharesIssuedUponCashlessExerciseOfWarrants		usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
	VBIV	Adjustments For Prior Periods From Adoption AdjustmentsForPriorPeriodsFromAdoption		usd
	VBIV	Warrants Modification In Connection With Debt Amendment WarrantsModificationInConnectionWithDebtAmendment		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear		usd
CY2021	VBIV	Contract With Customer Liability Currency Translation ContractWithCustomerLiabilityCurrencyTranslation		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37769
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Floor 3
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	864000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	526000	usd
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	830-3031
	dei	Security12b Title Security12bTitle	Common Shares, no par value per share
	dei	Trading Symbol TradingSymbol	VBIV
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	258257494	shares
CY2022Q2	us-gaap	Cash Cash	82414000	usd
CY2021Q4	us-gaap	Cash Cash	121694000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	135000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	4050000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2576000	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1685000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2373000	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	4468000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3633000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	92752000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	130284000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1396000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1259000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11015000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11037000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3382000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3344000	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	61379000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	62091000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	2237000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	2261000	usd
CY2022Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	79409000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	79992000	usd
CY2022Q2	us-gaap	Assets Assets	172161000	usd
CY2021Q4	us-gaap	Assets Assets	210276000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5617000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4280000	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	24380000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	26941000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	105558000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	143882000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	172161000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11421000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15084000	usd
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	8780000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	891000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	839000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	40532000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32586000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1878000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2277000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21163000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	28441000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2507000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2516000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	523000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	574000	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	26071000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	33808000	usd
CY2022Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2021Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	258257494	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	258257494	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	258250273	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	258250273	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	442286000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	442235000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	83757000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	81583000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	22774000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1565000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-443259000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-378371000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	210276000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	346000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	142000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	472000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	443000	usd
CY2022Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2522000	usd
CY2021Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2634000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5276000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5046000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5643000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4582000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8005000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9367000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26014000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16114000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	23249000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	16583000	usd
	us-gaap	Operating Expenses OperatingExpenses	39295000	usd
	us-gaap	Operating Expenses OperatingExpenses	32581000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-22903000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16441000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38823000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32138000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	901000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	845000	usd
	us-gaap	Interest Expense InterestExpense	1841000	usd
	us-gaap	Interest Expense InterestExpense	2657000	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-21895000	usd
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-190000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-26289000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-328000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45699000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17476000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-66953000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35123000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-45699000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-17476000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-66953000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-35123000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	19236000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1370000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	24339000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1713000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26463000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16106000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42614000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33410000	usd
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	258257494	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	255142550	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	258257095	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	252884284	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	143882000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	681000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2502000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21254000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5103000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4959000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4562000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	129564000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	821000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2012000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1015000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	921000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	129564000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2457000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-45699000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	19236000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	105558000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	171705000	usd
CY2021Q1	VBIV	Stock Issued During Period Value Issued For Financing Transaction Net Of Financing Costs StockIssuedDuringPeriodValueIssuedForFinancingTransactionNetOfFinancingCosts	21417000	usd
CY2021Q1	VBIV	Common Shares Value Issued Upon Exercise Of Warrants CommonSharesValueIssuedUponExerciseOfWarrants	52000	usd
CY2021Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2000000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2139000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-17647000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments And Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax	-54000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	397000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	180009000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	180009000	usd
CY2021Q2	VBIV	Stock Issued During Period Value Issued For Financing Transaction Net Of Financing Costs StockIssuedDuringPeriodValueIssuedForFinancingTransactionNetOfFinancingCosts	861000	usd
CY2021Q2	VBIV	Common Shares Value Issued Upon Exercise Of Warrants CommonSharesValueIssuedUponExerciseOfWarrants	29000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2423000	usd
CY2021Q2	VBIV	Modification Of Warrants Previously Issued ModificationOfWarrantsPreviouslyIssued	867000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-17476000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments And Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax	54000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1316000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	168083000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-66953000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-35123000	usd
	VBIV	Inventory Reserve InventoryReserve	353000	usd
	VBIV	Inventory Reserve InventoryReserve	720000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-26337000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-278000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	134000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2225000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	563000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-653000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-73000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	917000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1881000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	215000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	298000	usd
	VBIV	Increase Decrease In Operating Right Of Use Assets IncreaseDecreaseInOperatingRightOfUseAssets	668000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	135027000	usd
	VBIV	Increase Decrease In Operating Right Of Use Assets IncreaseDecreaseInOperatingRightOfUseAssets	-543000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1248000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	62091000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	905000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2097000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	41000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-175000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-2021000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	10459000	usd
	VBIV	Operating Lease Proceeds And Payments OperatingLeaseProceedsAndPayments	-674000	usd
	VBIV	Operating Lease Proceeds And Payments OperatingLeaseProceedsAndPayments	540000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37375000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17362000	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	25151000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1592000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	960000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1592000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24191000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	23030000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	743000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	12000000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	22000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	81000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34346000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-325000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-39280000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	41202000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	121694000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	93825000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	82414000	usd
	us-gaap	Interest Paid Net InterestPaidNet	811000	usd
	VBIV	Adjustments For Prior Periods From Adoption AdjustmentsForPriorPeriodsFromAdoption	681000	usd
	VBIV	Warrants Modification In Connection With Debt Amendment WarrantsModificationInConnectionWithDebtAmendment	867000	usd
	us-gaap	Stock Issued1 StockIssued1	4298000	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2000000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	757000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	122000	usd
	VBIV	Share Issuance Costs Included In Accounts Payable And Other Current Liabilities ShareIssuanceCostsIncludedInAccountsPayableAndOtherCurrentLiabilities	67000	usd
	VBIV	Share Issuance Costs Included In Accounts Payable And Other Current Liabilities ShareIssuanceCostsIncludedInAccountsPayableAndOtherCurrentLiabilities	9000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80F_eus-gaap--NatureOfOperations_z67wpMlTiXl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_823_zzxLKZoiP7K6">NATURE OF BUSINESS AND CONTINUATION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate Overview</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VBI Vaccines Inc. (the “Company” or “VBI”) was incorporated under the laws of British Columbia, Canada on <span id="xdx_90B_edei--EntityIncorporationDateOfIncorporation_c20220101__20220630_zcO5h29TMPUk" title="Entity incorporation, date of incorporation">April 9, 1965</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its wholly-owned subsidiaries, VBI Vaccines (Delaware) Inc., a Delaware corporation (“VBI DE”); VBI DE’s wholly-owned subsidiary, Variation Biotechnologies (US), Inc., a Delaware corporation (“VBI US”); Variation Biotechnologies, Inc. a Canadian company and the wholly-owned subsidiary of VBI US (“VBI Cda”); and SciVac Ltd. an Israeli company (“SciVac”); SciVac Hong Kong Limited (“SciVac HK”) and VBI Vaccines B.V a Netherlands company (“VBI BV”), are collectively referred to as the “Company”, “we”, “us”, “our”, or “VBI”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s registered office is located at Suite 1700, Park Place, 666 Burrard Street, Vancouver, BC V6C 2X8 with its principal office located at 160 Second Street, Floor 3, Cambridge, MA 02142. In addition, the Company has manufacturing facilities located in Rehovot, Israel and research facilities located in Ottawa, Ontario, Canada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal Operations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VBI Vaccines Inc. (“VBI”) is a commercial stage biopharmaceutical company driven by immunology in the pursuit of prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B (“HBV”), COVID-19 and coronaviruses, and cytomegalovirus (“CMV”), as well as aggressive cancers including glioblastoma (“GBM”). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ongoing COVID-19 pandemic has materially negatively affected and continues to affect the global economy, and there is continued severe uncertainty about the duration and intensity of the impacts of the pandemic. As a result, the Company’s business and results of operations have also been adversely affected and could continue to be adversely affected by COVID-19 which has necessitated restricting the number of personnel in the Company’s research laboratories and manufacturing facility at any given point in time, and has slowed recruitment to clinical trials. The extent to which the COVID-19 pandemic will continue to impact our business will depend on future developments, which are highly uncertain and cannot be predicted. We do not yet know the full extent of potential delays or impacts on our business, our clinical studies, our research programs, the recoverability of our assets, and our manufacturing; however, the COVID-19 pandemic may continue to disrupt or delay our business operations, including with respect to efforts relating to potential business development transactions, and it could continue to disrupt the marketplace which could have an adverse effect on our operations. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Going Concern</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company faces a number of risks, including but not limited to, uncertainties regarding the success of the development and commercialization of its products, demand and market acceptance of the Company’s products, and reliance on major customers. The Company anticipates that it will continue to incur significant operating costs and losses in connection with the development and commercialization of its products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had an accumulated deficit of $<span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20220630_zBfqXDAM69Ok" title="Accumulated deficit">443,259</span> as of June 30, 2022 and cash outflows from operating activities of $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20220101__20220630_zTLAeocUBXV5" title="Net cash provided by (used in) operating activities">37,375</span> for the six months ended June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will require significant additional funds to conduct clinical and non-clinical trials, commercially launch our products, and achieve regulatory approvals. Additional financing may be obtained from the issuance of equity securities, the issuance of additional debt, structured asset financings, government or non-governmental organization grants or subsidies, and/or revenues from potential business development transactions, if any. There is no assurance the Company will manage to obtain these sources of financing, if required. The above conditions raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 1, 2022, we received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“NASDAQ”) indicating that, based upon the closing bid price of our common shares for the 30 consecutive business day period between May 18, 2022 through June 30, 2022, we did not meet the minimum bid price of $<span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20220702__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zVi3BX6fBB78" title="Bid price">1.00</span> per share required for continued listing on The NASDAQ Capital Market pursuant to NASDAQ Listing Rule 5550(a)(2). The letter also indicated that we will be provided with a compliance period of 180 calendar days, or until December 28, 2022 (the “Compliance Period”), in which to regain compliance pursuant to NASDAQ Listing Rule 5810(c)(3)(A).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In order to regain compliance with NASDAQ’s minimum bid price requirement, our common shares must maintain a minimum closing bid price of $<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20220702__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zfJNBjE7rt8g" title="Bid price">1.00</span> for a minimum of ten consecutive business days during the Compliance Period. In the event that we do not regain compliance by the end of the Compliance Period, we may be eligible for additional time to regain compliance. To qualify, we will be required to meet the continued listing requirement for the market value of our publicly held shares and all other initial listing standards for NASDAQ, with the exception of the bid price requirement, and will need to provide written notice of our intention to cure the deficiency during the second compliance period, by effecting a reverse stock split if necessary. If we meet these requirements, we may be granted an additional 180 calendar days to regain compliance. We have not regained compliance as of the date of this Form 10-Q, and if we fail to regain compliance during the Compliance Period or any subsequent grace period granted by NASDAQ, our common shares will be subject to delisting by NASDAQ, which could seriously decrease or eliminate the value of an investment in our common shares and result in significantly increased uncertainty as to the Company’s ability to raise additional capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments recognized in the condensed consolidated balance sheet consist of cash, accounts receivable, other current assets, accounts payable, and other current liabilities. The Company believes that the carrying value of its current financial instruments approximates their fair values due to the short-term nature of these instruments. The Company does not hold any derivative financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of the Company’s other long-term assets approximate their respective fair values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1965-04-09
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-443259000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37375000	usd
CY2021Q4	VBIV	Deferred Funding Current DeferredFundingCurrent	10183000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	28441000	usd
CY2022Q2	VBIV	Other Current Liabilities OtherCurrentLiabilities	1565000	usd
CY2021Q4	VBIV	Other Current Liabilities OtherCurrentLiabilities	1463000	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	24380000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	26941000	usd
CY2020Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.52
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	180000	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	911000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	645000	usd
CY2022Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	2959000	usd
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1931000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	4050000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2576000	usd
CY2020Q2	VBIV	Intrinsic Value Of Beneficial Conversion Feature Recorded To Additional Paid In Capital IntrinsicValueOfBeneficialConversionFeatureRecordedToAdditionalPaidInCapital	2577000	usd
CY2022Q2	us-gaap	Government Contract Receivable GovernmentContractReceivable	2313000	usd
CY2021Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	1438000	usd
CY2022Q2	VBIV	Other Current Assets OtherCurrentAssets	2155000	usd
CY2021Q4	VBIV	Other Current Assets OtherCurrentAssets	2195000	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	4468000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3633000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	62169000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-664000	usd
	VBIV	Finite Lived Intangible Assets Cumulative Impairment Charge FiniteLivedIntangibleAssetsCumulativeImpairmentCharge	-300000	usd
	VBIV	Finite Lived Intangible Assets Cumulative Currency Translation FiniteLivedIntangibleAssetsCumulativeCurrencyTranslation	174000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	61379000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	62169000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-660000	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	32224000	usd
CY2021	VBIV	Finite Lived Intangible Assets Cumulative Impairment Charge FiniteLivedIntangibleAssetsCumulativeImpairmentCharge	-300000	usd
CY2021	VBIV	Finite Lived Intangible Assets Cumulative Currency Translation FiniteLivedIntangibleAssetsCumulativeCurrencyTranslation	882000	usd
CY2022Q2	VBIV	Interest Income InterestIncome	179000	usd
CY2022Q2	us-gaap	Goodwill Gross GoodwillGross	8714000	usd
CY2022Q2	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	6292000	usd
CY2022Q2	VBIV	Goodwill Cumulative Currency Translation GoodwillCumulativeCurrencyTranslation	185000	usd
CY2022Q2	VBIV	Goodwill Net GoodwillNet	2237000	usd
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	8714000	usd
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	6292000	usd
CY2021Q4	VBIV	Goodwill Cumulative Currency Translation GoodwillCumulativeCurrencyTranslation	161000	usd
CY2021Q4	VBIV	Goodwill Net GoodwillNet	2261000	usd
CY2022Q2	VBIV	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	7600000	usd
CY2021Q4	VBIV	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	8196000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4199000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2294000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2377000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4805000	usd
CY2022Q2	VBIV	Deferred Funding Current DeferredFundingCurrent	8639000	usd
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	8780000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21163000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26033127	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20860479	shares
CY2022Q2	VBIV	Long Term Debt Net LongTermDebtNet	29943000	usd
CY2021Q4	VBIV	Long Term Debt Net LongTermDebtNet	28441000	usd
CY2022Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	669000	usd
CY2021Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	481000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1276000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	870000	usd
CY2022Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	411000	usd
CY2021Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	401000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	821000	usd
CY2018Q4	VBIV	Additional Potential Regulatory And Sales Milestone Payments AdditionalPotentialRegulatoryAndSalesMilestonePayments	117500000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2012000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	142000	usd
CY2021Q2	VBIV	Interest Income InterestIncome	37000	usd
	VBIV	Interest Income InterestIncome	256000	usd
	VBIV	Interest Income InterestIncome	225000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	901000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	845000	usd
	us-gaap	Interest Expense InterestExpense	1841000	usd
	us-gaap	Interest Expense InterestExpense	2657000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	19492000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	12732000	usd
CY2022Q2	VBIV	Long Term Debt1 LongTermDebt1	32224000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	472000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	443000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9317	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9713	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0171	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0054	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M29D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.40
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	2457000	usd
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	2423000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4959000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4562000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	346000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	451000	usd
CY2022Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2742000	usd
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3104000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2803000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	38000	usd
	VBIV	Contract With Customer Liability Currency Translation ContractWithCustomerLiabilityCurrencyTranslation	23000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2742000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	864000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1878000	usd
	VBIV	Description Of Vaccine Development DescriptionOfVaccineDevelopment	On March 9, 2021, the Company and CEPI announced the CEPI Funding Agreement, to develop eVLP vaccine candidates against SARS-COV-2 variants, including the Beta variant, also known as the B.1.351 variant and as 501Y.V2, first identified in South Africa. CEPI agreed to provide up to $33,018 to support the advancement of VBI-2905, a monovalent eVLP candidate expressing the pre-fusion form of the spike protein from the Beta variant strain, through Phase I clinical development. This funding will also support preclinical expansion of additional multivalent vaccine candidates designed to evaluate the potential breadth of our eVLP technology. The preclinical expansion is intended to develop clinic-ready vaccine candidates capable of addressing emerging variants.
	VBIV	Funding Received FundingReceived	19327000	usd
CY2022Q2	VBIV	Deferred Funding Current DeferredFundingCurrent	8639000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	895000	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	340000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	683000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M23D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	648000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1176000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1064000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	575000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	574000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	169000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4206000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	808000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3398000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	891000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2507000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	346000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	142000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	472000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	443000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
0001493152-22-021559-index-headers.html	Edgar Link	pending
0001493152-22-021559-index.html	Edgar Link	pending
0001493152-22-021559.txt	Edgar Link	pending
0001493152-22-021559-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vbiv-20220630.xsd	Edgar Link	pending
vbiv-20220630_cal.xml	Edgar Link	unprocessable
vbiv-20220630_lab.xml	Edgar Link	unprocessable
vbiv-20220630_pre.xml	Edgar Link	unprocessable
vbiv-20220630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq

2022 Q3 Form 10-Q Financial Statement

#000149315222021559 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VBIVQ VBI Vaccines Inc/BC Stock $vbivq

2022 Q3 Form 10-Q Financial Statement

#000149315222021559 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq